Our key strength is that we have strong in-house R&D expertise, which has allowed us to develop a differentiated portfolio of pharmaceutical products that gives us a competitive advantage in the markets in which we operate.
Attributed with many firsts to introduce pharmaceutical products such as Troxipide and Ferric Carboxymaltose and most of our range of chiral molecules such as S-Amlodipine, S-Metoprolol and S-Atenolol
In the process of developing novel drug delivery systems based on the liposomal and nanotechnology platforms. Also identified several antifungal, antibiotic and oncology products that will be developed using these platforms
Effectively developed and marketed 11 chiral molecules which have demonstrated greater efficacy , safety and require lesser dosage than their non-chiral counterparts